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Beyond Statistics:  
The Economic Content of Risk Scores†
By Liran Einav, Amy Finkelstein, Raymond Kluender, and Paul Schrimpf*
“Big data” and statistical techniques to score potential transactions 
have transformed insurance and credit markets. In this paper, we 
observe that these widely-used statistical scores summarize a much 
richer heterogeneity, and may be endogenous to the context in which 
they get applied. We demonstrate this point empirically using data 
from Medicare Part D, showing that risk scores confound underlying 
health and endogenous spending response to insurance. We then illus-
trate theoretically that when individuals have heterogeneous behav-
ioral responses to contracts, strategic incentives for cream-skimming 
can still exist, even in the presence of “perfect” risk scoring under a 
given contract. (JEL C55, G22, G28, H51, I13)
Over the last two decades, many markets have been transformed by the increased use of information technology, “big data,” and statistical techniques. Credit 
and insurance markets are two leading examples (Edelberg 2006; Brown et al. 2014; 
Einav, Jenkins, and Levin 2013). Nowadays, it is almost impossible to obtain credit 
or insurance without providing a long list of personalized information, which pri-
vate lenders and insurance providers use to provide individually-customized prices 
or contracts. The government also actively uses such “risk scores” to regulate and 
reimburse private providers. In credit markets, for example, the government uses 
FICO scores—designed to predict an individual’s default risk—to regulate the 
availability and terms of private mortgages. In the context of health insurance, the 
government uses health spending risk scores—designed to predict an individual’s 
medical spending—to set Medicare reimbursement rates for private insurers. The 
state Health Insurance Exchanges created by the 2010 Affordable Care Act have 
increased interest in how best to design and use health spending risk scores in reg-
ulating government reimbursement of private insurance offered on the exchanges.
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These types of scoring algorithms predominantly rely on widely available pre-
dictive modeling techniques, which are commonly used in statistics and computer 
science. Typically one begins with a large individual-level dataset that contains a 
key outcome one is trying to predict (such as medical spending or default on a loan) 
and a long and rich list of potential regressors; the creators of the algorithm then 
deploy state-of-the-art predictive models to select regressors and obtain the “best” 
predictive model.
Our paper is motivated by the observation that the outcomes that risk scores are 
designed to predict, such as loan default or medical spending, are, naturally, eco-
nomic as well as statistical objects. While these outcomes may depend on certain 
individual characteristics that are invariant to the contract an individual chooses, 
they may also be affected by individual behavior. This behavior may well be endog-
enous to the context. Crucially, the behavioral response to the context may itself be 
heterogeneous across individuals.
The unidimensional risk score, however, is not designed to distinguish differ-
ences across individuals in their contract-invariant individual characteristics from 
differences in their behavioral response to another contract. Therefore, public reim-
bursement based on existing risk scores can give private providers incentives to 
cream-skim customers whose behavior under the contract is likely to make them 
lower cost than the risk score would predict. This suggests that risk scoring should 
be treated as a partially economic, rather than purely statistical, object, with proper-
ties that may need to be customized to a particular context and objective.
While this point is quite general, we develop and illustrate it in the particular 
context of the health spending risk scores that Medicare assigns to Medicare bene-
ficiaries. These risk scores predict Medicare spending in traditional fee for service 
Medicare as a function of the beneficiaries’ demographics and medical diagnoses 
in the previous year. They are used, among other things, to set reimbursement rates 
to private providers of different Medicare Part D prescription drug insurance plans, 
and to private providers of Medicare Advantage (MA) plans, privately run managed 
care plans that nowadays enroll almost a third of Medicare beneficiaries.
Risk scoring is a natural way for the government to try to prevent—or at least 
reduce—cherry picking of low cost individuals by private firms (Newhouse 1996). 
By adjusting reimbursement based on observable individual characteristics that cor-
relate with the individual’s cost to the private firm, the government can try to reduce 
these cream-skimming incentives. The key point of departure of this paper is to 
consider the possibility that an individual’s cost to the provider partly reflects the 
individual’s behavioral response to the provider’s contract, and that this behavioral 
response may differ across individuals—just as the standard, statistical, cost-related 
characteristics of the individual may differ—but will not be captured by current risk 
scoring practices.
We illustrate these points empirically in the specific context of the Medicare 
Part D prescription drug program. The introduction of prescription drug coverage in 
2006, which constituted the largest expansion of benefits in Medicare’s  half-century 
of existence, accounts for about 11 percent of total Medicare spending (Kaiser 
Family Foundation 2014, 2015). Medicare Part D enrollees can choose among 
 different prescription drug plans offered by private insurers. Medicare reimburses 
VoL. 8 no. 2 197einav et al.: beyond statistics: the economic content of risk scores
private plans as a function of the “Part D risk scores” for their enrollees; these pre-
dict a beneficiary’s prescription drug spending as a function of demographics and 
prior medical diagnoses.
We describe the data and the empirical strategy in Section I. Our research design 
exploits the famous “donut hole,” or “gap,” in Part D coverage, within which insur-
ance becomes discontinuously much less generous at the margin. We previously used 
this research design, together with detailed microdata on prescription drug claims 
of Medicare Part D beneficiaries from 2007 to 2009, to help identify the behavioral 
response of drug utilization to cost sharing (Einav, Finkelstein, and Schrimpf 2015). 
Here, in Section II, we use the same machinery to provide graphical evidence on two 
distinct, new results which are the focus of the current paper.
First, we show that two dimensions of heterogeneity are present and visible in 
the data. Unremarkably, we document heterogeneity in health; there are clear and 
expected relationships between annual drug spending and various individual char-
acteristics, such as age or the presence of specific chronic conditions. More inter-
estingly, we also document heterogeneity in the individual’s utilization response to 
the contract. Specifically, we find that those who reduce their drug spending on the 
margin in response to the kink in the budget set created by the donut hole are more 
likely to be male, younger, and healthier, presumably reflecting their greater flexi-
bility to forego drug purchases when the price increases.
Our second key empirical finding is that current risk scores do not capture this 
second dimension of heterogeneity. Risk scores increase smoothly with annual 
spending, but without exhibiting any noticeable pattern around the kink. This illus-
trates that the current risk scores do not capture differences across individuals in 
their behavioral response to consumer cost sharing. This is by design; the creation 
of risk scores is currently treated as a statistical exercise, designed to generate the 
best predictor of an individual’s costs under the observed environment, rather than 
an economic model of what their costs might be under an alternative contract.
In Section III we consider theoretically some of the potential implications of these 
empirical findings. In particular, we show that when individuals are heterogeneous 
not only in their underlying health but also in their utilization response to a health 
insurance contract, risk scores that are “perfect” in the statistical sense of capturing 
all residual heterogeneity under a given contract can still create cream-skimming 
incentives for private providers. We stop short of the more ambitious undertaking of 
estimating an equilibrium model of supply and demand for different health insur-
ance contracts that would allow us to provide an empirical assessment of the impli-
cations of observed and alternative risk scoring for equilibrium cream-skimming. 
This is a natural direction for further work.
Our paper contributes to a large literature on risk adjustment in health insurance 
markets, which was reviewed in Van de Ven and Ellis (2000) and Ellis (2008). Much 
of this literature has focused on predictive (statistical) modeling. A recent focus 
has been on the fact that risk adjustment relies on diagnoses recorded in clinical 
and administrative records, which may reflect differences in diagnostic and treat-
ment practices across insurers and providers, in addition to underlying health (Song 
et al. 2010). There has also been attention to the incentives for cream-skimming and 
“gaming” that such risk scores provide. However, the focus of the existing analysis 
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of cream-skimming is that in the presence of imperfect prediction of individual risk, 
private insurers have an incentive to try to attract (“cream skim”) individuals who, 
given their predicted risk, have (imperfectly priced) characteristics that (in expecta-
tion) generate lower realized risk.1 Glazer and McGuire (2000) provide the classic 
theoretical framework for this type of strategic cream-skimming; they show that 
in the presence of imperfect risk adjustment, the relationship between reimburse-
ment and predicted risk should be amplified in order to minimize cream-skimming 
incentives. Empirically, two recent papers—Brown et al. (2014) and Newhouse 
et al. (2012)—use a similar framework to examine providers’ strategic response to 
imperfect risk scoring in the context of Medicare Advantage.
The key distinction between the current paper and this existing risk-adjustment 
literature is that the latter is focused on the problem of imperfect risk adjustment in 
an environment with unidimensional heterogeneity. In this setting, a “perfect” (in a 
statistical sense) risk prediction model would eliminate cream-skimming incentives, 
and the market would operate like any traditional product market. Although the 
assumption of imperfect risk adjustment is a natural one, the cream skimming incen-
tives considered by the existing literature could, at least in principle, be eliminated 
with rich enough data and sophisticated enough statistical modeling, thus obviating 
the need for economic models. In contrast, our focus is on a different challenge in 
using risk scores, a challenge that cannot—even in principle—be solved with rich 
enough data and perfect scoring. Our key observation is that the outcome the risk 
score attempts to predict is partially determined by individuals’ behavioral choices, 
and these may vary with the contract. Therefore, even perfect prediction of the out-
come under a given contract (“perfect” risk adjustment in the sense of the prior 
literature) would not suffice, and an economic model of behavior is needed to think 
about optimal reimbursement policy when coverage contracts differ.
Our paper also relates to a large “moral hazard” literature in health economics 
on the impact of insurance contracts on medical care use in general, and more spe-
cifically to a smaller “moral hazard” literature in the context of Medicare Part D 
(Duggan and Scott Morton 2010; Einav, Finkelstein, and Schrimpf 2015). In con-
trast to most of this literature, which has focused on average behavioral responses, 
our focus here is on the potential individual heterogeneity in the behavioral response 
and its implications (in this case, for risk scoring). In this sense, our paper relates 
to previous work analyzing the role of heterogeneity in the behavioral response in 
contributing to adverse selection in an employer-provided health insurance setting 
(Einav et al. 2013, Shepard 2015).
I. Data and Empirical Strategy
The central premise behind our analysis of risk scoring is that an individual’s 
medical spending is determined by both underlying health and economic choices, 
both of which are potentially heterogeneous across individuals. We demonstrate 
1 In addition, another branch of the literature notes that insurers also have an incentive to “upcode” the individ-
ual components that enter into the risk-adjustment formula to increase a given individual’s reimbursement (Dafny 
2005, Geruso and Layton 2014). 
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this simply and visually, using data from Medicare Part D, the prescription drug 
coverage component of Medicare that was added in 2006. As of November 2012, 
32 million people (about 60 percent of Medicare beneficiaries) were enrolled in 
Part D, with expenditures projected to be $60 billion in 2013, or about 11 percent of 
total Medicare spending (Kaiser Family Foundation 2014, 2015). Unlike Medicare 
Parts A and B for hospital and doctor coverage, which provide a uniform public 
insurance package for all enrollees (except those who select into the managed care 
option, Medicare Advantage), private insurance companies offer various Medicare 
Part D contracts, and are reimbursed by Medicare as a function of their enrollees’ 
risk scores.
While the exact features of the plans offered vary, they are all based around a 
standard design, shown in Figure 1. The discontinuous increase in the out-of-pocket 
price individuals face when they cross into the “donut hole” (or “gap”; see Figure 1) 
provides the research design that enables us to detect the responsiveness of individu-
als to the out-of-pocket price. As discussed in more detail in our earlier work (Einav, 
Finkelstein, and Schrimpf 2015), standard price theory suggests that individuals’ 
annual spending will “bunch” around the convex kink in the budget set created by 
the gap. Importantly, the extent of bunching should be greater and more noticeable 
for individuals who are associated with greater price sensitivity.
A. Data
We use data on a 20 percent random sample of all Medicare Part D beneficiaries 
over the years 2007–2009. The data include basic demographic information (such as 
age and gender) and detailed information on the cost sharing characteristics of each 
beneficiary’s prescription drug plan. We also observe detailed, claim-level informa-
tion on our beneficiaries’ Medicare utilization from 2006–2010. This includes both 
prescription drug purchases (covered under Medicare Part D), as well as inpatient, 
emergency room, and outpatient (non-emergency) use (covered under Medicare 
Parts A and B). Finally, we observe mortality through 2010.
We use the same sample that we used in Einav, Finkelstein, and Schrimpf (2015) 
with the additional restriction that beneficiaries were enrolled in Medicare in the 
previous year. It excludes various groups of beneficiaries for whom the empirical 
strategy is not applicable, such as individuals in Medicare Advantage and certain 
low income individuals for whom the basic benefit design we are studying does 
not apply. We also limit the analysis to individuals aged 65 and over. See Einav, 
Finkelstein, and Schrimpf (2015) for a complete discussion and details of the sample.
Our analysis sample consists of 3.7 million beneficiary-years (1.6 million unique 
beneficiaries) during the years 2007–2009. The average age in our sample is 76, 
and about two-thirds of the individuals are females. Average annual, per-beneficiary 
drug spending is just over $1,900 dollars; on average, approximately $800 are paid 
out of pocket. Spending is very right skewed: about 5 percent of beneficiaries have 
no annual drug spending, median spending is about $1,400, and the ninetieth per-
centile is about $4,000.
As noted, there is variation in the insurance contract design, including the extent 
of any coverage in the gap. On average, a beneficiary in our sample faces a 60 cent 
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increase in out-of-pocket spending for every dollar spent, as his annual spending 
hits the kink. Specifically, we estimate that average out-of-pocket cost sharing in 
our sample is 34 cents on the dollar below the kink and 93 cents on the dollar in the 
gap. The exact location of the kink, as a function of total drug spending, also varies 
across observations in our sample depending on the year, but on average it hits at 
roughly the seventy-fifth percentile of the drug spending distribution.
We use the Centers of Medicare and Medicaid’s Services’ (CMS) 2012 RxHCC 
risk-adjustment model which is designed to predict a beneficiary’s prescription drug 
spending in year  t as a function of their inpatient and outpatient diagnosis data from 
year  t − 1 , as well as demographic information (including gender, age, and the orig-
inal reason for entitlement to Medicare). The model takes more than 14,000 disease 
(ICD-9) codes and aggregates them into 167 “condition categories.” The model 
imposes a hierarchy on the condition categories in order to group them together 
into clinically meaningful diagnoses, which predict costs. These final “hierarchical 
condition categories” (HCCs) are the level of diagnoses used to specify the risk-
score model, out of which the model selects those HCCs that are found to be most 
predictive of drug spending.
The final version of the risk-adjustment model uses an additively separable 
predictive model, which relies on risk-score coefficients that are associated with 
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Figure 1. Medicare Part D Standard Benefit Design (in 2008)
notes: The figure shows the standard benefit design in 2008. “Pre-kink coverage” refers to coverage prior to the 
Initial Coverage Limit (ICL), which is where there is a kink in the budget set and the gap, or donut hole, begins. 
The level at which catastrophic coverage kicks in is defined in terms of out-of-pocket spending (of $4,050), which 
we convert to the total expenditure amount provided in the figure. Once catastrophic coverage kicks in, the actual 
standard coverage specifies a set of copays (dollar amounts) for particular types of drugs; in the figure we use a 
7 percent coinsurance rate, which is the empirical average of these copays in our data.
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78 selected HCCs from year  t − 1 , a gender dummy variable, dummy variables for 
each five-year age bin, and a dummy variable associated with the original reason for 
Medicare entitlement. Predicted year- t drug spending is then computed by simply 
adding up all the risk-score coefficients that are associated with those dummy vari-
ables that are “turned on” for a given beneficiary. For an individual’s first year in 
Medicare (typically when he turns 65), when diagnosis information from the previ-
ous year is not available, a new-enrollee risk score is generated solely on the basis of 
the demographic information. All predictions are normalized by the prediction for a 
representative Part D beneficiary, who is assigned a risk score of 1.2
Private insurers submit annual bids to CMS for their projected costs of covering a 
Medicare Part D beneficiary with a risk score of 1 (excluding catastrophic coverage 
provided by CMS). CMS calculates the market’s average bid and multiplies it by 
an individual’s risk score to determine the direct subsidy paid to the private insurer. 
A similar methodology is used to reimburse private insurers providing Medicare 
Advantage coverage. Our sample average Part D risk score is 0.88, indicating that 
they are 12 percent less expensive to cover than the representative Part D beneficiary.
B. Empirical strategy
We use simple graphical illustrations of the average characteristics of individ-
uals as a function of total annual drug spending to illustrate the two dimensions 
of heterogeneity that are our focus: heterogeneity in health and heterogeneity in 
the behavioral response to the contract. Monotonic patterns of individual average 
 demographic characteristics and diagnoses as a function of total drug spending 
show the heterogeneity in health that is the focus of current risk scoring. Sharp 
deviations from these monotonic patterns around the kink in the budget set illustrate 
heterogeneity in the behavioral response to the contract.
Our strategy for detecting heterogeneity in the behavioral response to the contract 
builds on our prior work detecting the average behavioral response to the  contract 
from the fact that individuals bunch at the kink. Figure 2 replicates this prior 
bunching analysis from Einav, Finkelstein, and Schrimpf (2015). Because the kink 
location has changed from year to year (from $2,400 in 2007, to $2,510 in 2008, 
and $2,700 in 2009), in all our figures we normalize annual spending by the kink 
location. We plot the distribution of (normalized) annual spending (in $20 bins) 
for individuals whose spending is within $2,000 of the kink (on either side). This 
constitutes 66 percent of our sample. The presence of significant “excess mass,” 
or “bunching” of annual spending levels around the convex kink in the budget set 
(that is created by the gap) indicates the presence of a behavioral response to the 
increased consumer cost sharing at the kink. The response to the kink is apparent: 
there is a noticeable spike in the distribution of annual spending around the kink. In 
Einav, Finkelstein, and Schrimpf (2015) we presented this result in greater detail, 
showing how the location of the spike moves as the kink location changes from year 
2 CMS’ risk-adjustment models for Medicare Advantage operate in a similar way, except that they are designed 
to predict overall Medicare spending (not just drug spending), and include variables for Medicaid eligibility and a 
different selection of HCCs. 
202 AMErIcAn EconoMIc JournAL: APPLIED EconoMIcs APrIL 2016
to year and  analyzing the types of drugs that individuals appear to stop purchasing 
when they slow down their drug utilization and “bunch” at the kink.
In this paper, we focus instead on heterogeneity in the responsiveness across dif-
ferent groups of individuals, interpreting greater bunching around the kink for dif-
ferent populations as reflecting greater demand sensitivity to out-of-pocket price. We 
identify heterogeneity in this behavioral response by documenting sharp changes in 
the presence of specific individual characteristics around the kink. An individual 
characteristic (such as being male or having a particular health condition) that is 
overrepresented among individuals around the kink indicates that individuals with 
this characteristic have a greater behavioral response to the kink (and are therefore 
overrepresented around the kink). Conversely, a characteristic which is underrepre-
sented among individuals whose spending is around the kink suggests that individ-
uals with this characteristic are less responsive to the contract.
II. Results
A. Evidence of Two-Dimensional Heterogeneity
In Figure 3 we present several summary statistics on the beneficiaries by their 
spending bin. Summary statistics are mostly monotone in annual spending in 
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Figure 2. Bunching of Annual Spending around the Kink
notes: Total annual prescription drug spending on the x-axis is reported relative to the (year-specific) location of 
the kink, which is normalized to zero. The sample uses beneficiary-years in our 2007–2009 baseline sample whose 
annual spending is within $2,000 of the (year-specific) kink location. The points in the figure display the distribu-
tion of annual spending; each point represents the set of people who spent up to $50 above the value that is on the 
x-axis, so that the first point represents individuals who spent between −$2,000 and −$1,950 from the kink, the 
second point represents individuals between −$1,950 and −$1,900, and so on. We normalize the frequencies so that 
they add up to one for the range of annual spending shown. Observations = 2,506,305.
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Figure 3A. Variation in Demographics around the Kink
notes: Total annual prescription drug spending on the x-axis is reported relative to the (year-specific) location of 
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sent the 95 percent confidence interval for each point. Observations = 2,506,305.
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expected ways: individuals who spend more are older and sicker. This illustrates the 
heterogeneity in underlying health that current risk scoring is designed to capture.
The novel observation in Figure 3, however, is not the monotone pattern, but 
rather the noticeable non-monotone pattern around the kink for some of the indi-
vidual attributes. Recall that beneficiaries bunch around the kink (see Figure 2). 
Therefore, the distinct demographics around the kink location capture the distinct 
demographics of those beneficiaries who are more likely to bunch around the kink, 
or in other words, the more price-sensitive individuals.
Figure 3A shows the patterns of various demographics: age (panel A) and gender 
(panel B). Average age is generally monotonically increasing in annual spending, 
but there is a sharp dip in average age at the kink. Likewise, there is a sharp dip in 
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the probability of being female right around the kink. That is, we find that younger 
males are more likely to bunch around the kink, which we interpret as evidence that 
they are more price elastic.
Figure 3B examines the frequency of a handful of selected health conditions 
(HCCs) that enter the risk-adjustment formula. The frequency of each condition 
is generally increasing monotonically in annual spending, reflecting the fact that 
individuals with a given condition spend, on average, more. However, for some of 
the conditions there appear to be some noticeable non-monotone patterns around the 
kink. In particular, the probability of depression and congestive heart failure appear 
to dip slightly around the kink, suggesting that these conditions are associated with 
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Figure 3C. Variation in Subsequent Mortality and Healthcare Utilization around the Kink
notes: Total annual prescription drug spending on the x-axis is reported relative to the (year-specific) location of 
the kink, which is normalized to zero. The sample uses beneficiary-years in our 2007–2009 baseline sample whose 
annual spending is within $2,000 of the (year-specific) kink location. The points in the figure display the statis-
tic (for the subsequent coverage year, so covering the years 2008–2010) described on the y-axis for each group of 
beneficiaries who spent up to $50 above the value that is on the x-axis, so that the first point represents individuals 
who spent between −$2,000 and −$1,950 from the kink, the second point represents individuals between −$1,950 
and −$1,900, and so on. The small dots above and below the points represent the 95 percent confidence interval for 
each point. Observations = 2,506,305.
206 AMErIcAn EconoMIc JournAL: APPLIED EconoMIcs APrIL 2016
a lower drug use response to price. By contrast, some other health conditions—such 
as coronary artery disease or chronic obstructive pulmonary disease (COPD) and 
asthma—are not associated with any noticeable pattern around the kink, suggesting 
that these conditions are not associated with a price response.
Finally, Figure 3C examines mortality and non-drug healthcare utilization in 
the subsequent calendar year (year  t + 1 ) as a function of annual drug spending in 
the current year (year  t ). Specifically, we look at mortality for the full year ( t + 1 ) 
and emergency room (ER) visits, inpatient admissions, and (non-ER) outpatient 
visits during January to June of  t + 1 . Again, there is a natural monotone pattern: 
individuals who spend more on drugs in year  t are presumably sicker, and are there-
fore associated with greater non-drug healthcare utilization and greater mortality 
in the subsequent year. However, once again, there are distinct non-monotonicities 
around the kink. The probability of death in year  t + 1 drops sharply for those who 
are around the kink. The figure also shows some evidence that individuals who are 
approaching the kink in year  t are less likely to use other medical care (emergency 
room, non-emergency outpatient care, or inpatient care) in the first six months of 
year  t + 1 . The effect on the use of other medical care is weaker, as it is not based 
on a non-monotone pattern around the kink, but only relies on the local change in 
slope around the kink.
The interpretation of Figure 3C is a little more subtle. We interpret it as additional 
evidence that the individuals who are more price sensitive and therefore bunch at 
the kink are also healthier, as measured by their subsequent (non-drug) healthcare 
use and mortality rate.3 Of course, since subsequent health and healthcare use are 
potentially directly affected by current drug utilization decisions, it is possible that 
these results reflect a causal treatment effect of drug utilization (which varies across 
individuals depending on their price sensitivity) on health.
B. risk scores Do not capture Both Dimensions
Figure 4 illustrates the other key point of the paper: the current risk scores do not 
capture heterogeneity across individuals in their behavioral response to the contract. 
Figure 4A presents a similar analysis to those shown in Figure 3, except that we now 
summarize the risk scores that Medicare Part D assigns these individuals.
It shows an overall smooth, monotone pattern of average Part D risk score, 
reflecting (by design) that individuals with higher average spending have higher 
risk scores. Strikingly, however, the individuals around the kink (i.e., those who 
are more likely to be “bunchers”) appear to follow the increasing pattern of health 
spending risk scores, without any visible pattern around the kink. That is, the health 
spending risk score predicts well spending under the observed contract—as it is 
designed to do—without capturing (by design) the fact that some of this spending 
reflects a price response, which is endogenous to the coverage contract.
3 Interpreting these patterns as reflecting heterogeneity in underlying health (rather than an effect of drug spend-
ing on subsequent health) is also consistent with a related finding by Joyce, Zissimopoulos, and Goldman (2013), 
that the decline in drug purchases for diabetics who entered the gap is not associated with increased use of medical 
services. 
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There are two different possible ways to reconcile the evidence in Figure 3 that 
healthier individuals are more likely to bunch at the kink, with the evidence in 
Figure 4A that the Part D risk scores do not reflect any lower predicted spending for 
individuals at the kink. One is that the demographics that change sharply around the 
kink in Figure 3 are not quantitatively important in generating risk scores, and thus 
do not affect much the average risk scores in Figure 4. The other is that there are 
other components of the risk score that move in the opposite direction around the 
kink, thus offsetting the patterns presented in Figure 3. The interpretation does not 
affect our main point, which is that the current risk scores do not capture differences 
in spending that arise from differences in the behavioral response to the contract.
Our analysis suggests that the monotone pattern of risk scores through the kink 
in Figure 4A in fact reflects offsetting effects: the characteristics that exhibit greater 
propensity around the kink have a noticeable effect on risk scores, but they are offset 
by other characteristics that display the opposite pattern at the kink. To determine 
this, we generated a prediction of the value of each component of the risk score 
around the kink, using its values below the kink. That is, for each component of the 
risk score (age category, gender, and each specific HCC), we ran a linear regression 
based on the relationship between spending and that component of the risk score 
in the (−$2,000, −$200) range and then, using the estimated regression, gener-
ated predictions for that component in the (−$200, +$200) range. We then split the 
individual components into those that exhibited excess bunching around the kink 
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Figure 4A. Variation in “Endogenous” Risk Score around the Kink
notes: Total annual prescription drug spending on the x-axis is reported relative to the (year-specific) location of 
the kink, which is normalized to zero. The sample uses beneficiary-years in our 2007–2009 baseline sample whose 
annual spending is within $2,000 of the (year-specific) kink location. The points in the figure display the statistic 
described on the y-axis for each group of beneficiaries who spent up to $50 above the value that is on the x-axis, so 
that the first point represents individuals who spent between −$2,000 and −$1,950 from the kink, the second point 
represents individuals between −$1,950 and −$1,900, and so on. The small dots above and below the points repre-
sent the 95 percent confidence interval for each point. Observations = 2,506,305.
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(that is, those whose actual values in the (−$200, +$200) range was on average 
higher than the corresponding prediction in this range) and those that exhibited a 
dip around the kink (that is, those whose actual values in the (−$200, +$200) range 
was on average lower than the corresponding prediction in this range). We then 
produced two different versions of “predicted” overall risk scores. In one, we used 
the predicted values for those components that exhibit bunching around the kink 
and the actual values for the rest. In the other, we used the predicted values for those 
components that exhibit dips around the kink, and the actual values for the rest. If 
the components that exhibit bunching and dipping around the kink do not do so in 
a manner that is quantitatively important for the risk score, we would expect these 
two different versions of the predicted risk scores to lie very close to each other 
(and to the actual risk score) around the kink. Figure 4B shows that, in fact, the two 
different versions of the predicted risk scores lie apart from each other on either side 
of the actual risk score. This suggests that the patterns for individual components 
around the kink are quantitatively important, but offset each other. Table 1 shows 
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Figure 4B. Magnitude of Offsetting Effects
notes: Total annual prescription drug spending on the x-axis is reported relative to the (year-specific) location of 
the kink, which is normalized to zero. The sample uses beneficiary-years in our 2007–2009 baseline sample whose 
annual spending is within −$2,000 to +$200 of the (year-specific) kink location. The points in the figure display 
the statistic described on the y-axis for each group of beneficiaries who spent up to $50 above the value that is on 
the x-axis, so that the first point represents individuals who spent between −$2,000 and −$1,950 from the kink, the 
second point represents individuals between −$1,950 and −$1,900, and so on. Observations = 1,948,900. The light 
gray series presents the actual risk score, replicating Figure 4A. The top (gray squares) series shows the risk score 
generated by taking the predicted values of the risk score components that exhibit dips at the kink, and the actual 
values for the rest. The bottom (gray triangles) series shows the risk score generated by taking the predicted values 
of the risk-score components that exhibit bunching at the kink, and the actual values for the rest. The predictions 
for each component of the risk score is generated by fitting a trend in that component for spending more than $200 
under the kink (see text for more details).
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the underlying components that are most important in affecting the positive and 
negative shifts in risk scores around the kink.
C. A Quantitative Assessment of Heterogeneity in the Behavioral response
These findings document that there is heterogeneity in the behavioral response 
to cost sharing that is not captured by the risk score. A natural question is whether 
this has quantitatively important implications, not only at the kink, which is the 
focus of our research design, but more generally throughout the nonlinear budget set 
created by the contract. To answer this, one needs to develop and estimate a behav-
ioral model of healthcare spending under different contract designs, and investigate 
the extent to which an individual’s ranking in the spending distribution is the same 
under alternative contracts.
As we discuss in the next section, given that insurers could apply any nonlinear 
transformation to a given set of risk scores, the key role of a risk scoring system is 
Table 1—Components Underlying the Effect on Risk Scores around the Kink
Incidence around the kink Share of risk-
score differenceActual “Predicted” Difference
Panel A. Top ten components with positive kink incidence
Chronic obstructive pulmonary disease and
 asthma
0.1908 0.1784 0.0124 20.50%
Diabetes with complications 0.0908 0.0816 0.0091 19.13%
Breast, lung, and other cancers and tumors 0.0582 0.0520 0.0062 10.72%
Alzheimer’s disease 0.0203 0.0179 0.0024 9.32%
Diabetes without complications 0.2020 0.1962 0.0058 8.45%
Esophageal reflux and other disorders of 
 esophagus
0.2146 0.2082 0.0064 7.26%
Inflammatory bowel disease 0.0107 0.0093 0.0014 3.21%
Diabetic retinopathy 0.0278 0.0237 0.0041 3.20%
Parkinson’s disease 0.0127 0.0119 0.0009 3.06%
Major depression 0.0196 0.0187 0.0010 2.26%
Panel B. Top ten components with negative kink incidence
Hypertension 0.6531 0.6735 0.0203 33.48%
Disorders of lipoid metabolism 0.7344 0.7530 0.0186 21.63%
Osteoporosis, vertebral, and pathological 
 fractures
0.1730 0.1874 0.0144 13.13%
Open-angle glaucoma 0.0918 0.0999 0.0081 11.28%
Atrial arrhythmias 0.1361 0.1460 0.0099 5.99%
Congestive heart failure 0.1117 0.1148 0.0031 5.40%
Thyroid disorders 0.2525 0.2596 0.0071 2.64%
Coronary artery disease 0.3107 0.3116 0.0009 1.23%
Depression 0.0659 0.0668 0.0009 1.20%
Cereborvascular disease, except hemorrhage or 
 aneurysm
0.1513 0.1522 0.0009 0.59%
notes: The table presents the top ten components responsible for the positive and negative risk-score effect pre-
sented in Figure 4B. The  first column (“Actual”) reports the average value of the component around the kink (spe-
cifically, between −$200 and $200 of the kink, whose value is normalized to 0). The second column (“Predicted”) 
reports the average predicted value of each component, by extrapolating a linear relationship from the (−$2,000, 
−$200) range. The third column (“Difference”) reports the difference between actual and predicted. The last col-
umn (“Share of risk-score difference”) reports the share of each component in generating the positive (panel A) and 
negative (panel B) risk-score effect presented in Figure 4B. This is computed by multiplying the difference associ-
ated with each component (as reported in the third column) by the risk-score coefficient on that component in the 
risk-adjustment formula, and normalizing this product by the sum of all these products that are associated with pos-
itive (panel A) and negative (panel B) deviations around the gap.
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in its ordinal ranking of individuals in term of their expected risk. Thus, one way to 
assess the quantitative importance of the heterogeneity in the behavioral response 
to the contract design is to quantify the extent to which individuals’ position in the 
population’s expected risk distribution (that is, in the contract-specific risk-score 
distribution) gets reshuffled as they move across contracts. If heterogeneity in the 
behavioral response to the contract is not quantitatively important, individuals’ 
ranking would remain relatively stable across contracts.
The research design we have used thus far is not sufficient for such an exercise, 
as it doesn’t attempt to model health utilization behavior under alternative contract 
designs. However, we can shed some light on this question by using the model of 
healthcare utilization that we developed and estimated in our earlier, related work 
(Einav, Finkelstein, and Schrimpf 2015). There we develop a complete, dynamic 
behavioral model of the individual’s drug purchasing decisions under nonlinear 
 coverage contract, allowing for heterogeneity across individuals in both health risk 
and in the spending response to coverage. In our prior paper, we estimated the mod-
el’s parameters using the same dataset as in the current paper; the “bunching at 
the kink” we have examined here is one of the elements used for identification in 
estimating that model. In Appendix Table A1, we use the model estimates to predict 
spending under the standard contract shown in Figure 1, and then predict spending 
(for the same set of individuals and associated sequences of health shocks) for two 
alternative, counterfactual contracts. One is a “filled gap” contract that eliminates 
the gap by providing pre-gap cost sharing up to the catastrophic coverage limit; the 
Affordable Care Act aims to make this type of contract become the standard contract 
by 2020. A second contract is actuarially equivalent to the standard contract shown 
in Figure 1, but it eliminates the deductible in the standard contract, and instead 
offers higher cost sharing (of 38.9 cents for each dollar, instead of 25 cents) for 
spending below the gap.
Appendix Table A1 shows the extent to which individuals’ ranking in the spending 
distribution changes under alternative contracts, relative to their spending percentile 
under the standard contract presented in Figure 1. We split individuals into ventiles 
of spending under the standard contract, and report (for each ventile) the share of 
the individuals who are expected to stay within the same ventile, and the share 
that moves to other spending ventiles (up or down) under the alternative contract. 
Of course, expected spending is primarily driven by expected health, so the vast 
majority of individuals remain within the same spending ventile. Yet, as Appendix 
Table A1 shows, a nonnegligible share of individuals get reshuffled in their ranking, 
especially in the region where the price changes. For example, panel A shows that 
“filling” the coverage gap leads to a fair amount of “reshuffling” in the expected 
spending of high spenders, who are those who are most affected by the change in 
coverage in the gap. Panel B shows that eliminating the deductible leads to a fair 
amount of “reshuffling” in the expected spending of low spenders, who are those 
who are likely to be affected the most by the deductible.
This exercise illustrates the perils of using predicted spending under one contract 
to generate predicted spending (i.e., risk scores) under alternative contracts. The 
results in Appendix Table A1 show that if one generated a risk score based on spend-
ing under the standard contract and used it to predict spending under alternative 
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contracts, the generated risk scores would be highly imprecise for those regions of 
spending that are most affected by the alternative contract.
A natural follow-up question is how important this imprecision of risk scores 
would be for equilibrium cream skimming and market outcomes. Answering this 
question empirically would require not only a model of demand (that is, of health 
care utilization), but also a model of competition and pricing, which is beyond the 
scope of the current paper. Instead, in the next section we briefly explore theoreti-
cally some potential implications for cream skimming incentives and optimal risk 
adjustment.
III. Implications
The evidence in the preceding section established that Medicare’s risk scores 
reflect expected medical spending under the existing benefit design, and that this 
one-dimensional score hides a richer heterogeneity that determines medical spend-
ing. The multidimensional heterogeneity that determines medical spending reflects 
heterogenous price sensitivity as well as heterogeneous health. In this final section, 
we illustrate theoretically how reimbursement based on the (unidimensional) risk 
score can create incentives for private providers to cream-skim customers whose 
behavior under their private contract is likely to make them lower cost than the 
risk score would predict (as it is based on behavior under an alternative contract). 
Importantly, this incentive for cream-skimming cannot be combatted by richer sta-
tistical modeling of utilization behavior under a given contract.
Cream-skimming by providers of individuals who are lower cost than their risk 
score would suggest is the classic problem analyzed by theoretical and empirical 
work on risk scoring (Glazer and McGuire 2000, Newhouse et al. 2012, Brown et al. 
2014). In these existing analyses, if the risk scoring is “perfect” in a statistical sense 
(i.e., conditional on the risk score, there are no residual characteristics of the indi-
vidual that predict spending under a given contract) the cream-skimming problem 
goes away.4
However, once we enrich the model to allow individuals to have heterogeneous 
behavioral responses to the coverage contract, strategic incentives for cream skim-
ming can still exist, even in the presence of “perfect” risk scoring under a given con-
tract. This is because individuals of the same risk score (and hence same predicted 
medical spending in one particular contract) may have different predicted medical 
spending under a different contract, due to their differential behavioral responses. 
Providers therefore can have an incentive to try to design contracts to attract those 
whose behavioral response to an alternative contract makes them have a lower 
expected cost than their risk score would predict.
4 Interestingly, Brown et al. (2014) have recently highlighted that improvements in risk scoring that do not make 
the score “perfect” may, perversely, exacerbate cream-skimming. 
212 AMErIcAn EconoMIc JournAL: APPLIED EconoMIcs APrIL 2016
A. A stylized Framework
We start with a stylized model of healthcare utilization that emphasizes two forms 
of individual heterogeneity. The model is drawn from our earlier work (Einav et al. 
2013), which used a similar framework to examine a related question in a different 
setting.
An individual in the model is defined by a two-dimensional type, ( λ, ω ). In this 
definition,  λ ≥ 0 denotes the individual’s underlying health and  ω ≥ 0 denotes 
his price sensitivity of demand for medical care, or how responsive healthcare uti-
lization choices are to insurance coverage. We focus on these two different dimen-
sions that determine healthcare utilization.5 We assume, in the spirit of the empirical 
results in the last section, that they cannot be separately distinguished by a unidi-
mensional risk score.
For illustrative purposes, we consider individuals with a linear insurance cover-
age with a price of healthcare of  c ∈ [0, 1] . That is, for every dollar of spending on 
healthcare, the individual pays  c and the insurance provider pays  1 − c .
Individuals make their healthcare utilization decision to maximize a tradeoff 
between health and money (residual income). Health depends on one’s underlying 
health  λ but is increasing in his monetized healthcare use (or medical spending) 
given by  m ≥ 0. Residual income  y(m) is decreasing in  m at a rate that depends 
on the health insurance contract’s  c . More specifically, individual utility is given by
(1)  u(m; λ, ω) =  [ (m − λ) −  1 ___ 2ω  (m − λ) 2 ] +  (y − c · m) . 
The first component (in square brackets) captures the individual’s health, which 
can be improved by greater utilization  m . The second component captures residual 
income, which is given by the individual’s income  y net of his out-of-pocket spend-
ing  c · m .
Optimal medical spending  m ∗ is chosen to maximize utility, that is by solving 
max m≥0  u(m; λ, ω) . This yields the first-order condition
(2)  m ∗ (λ, ω) = λ + ω (1 − c) . 
Optimal medical spending depends on the individual’s underlying health ( λ ), the 
out-of-pocket price of medical care ( c ), and the responsiveness of spending to that 
price ( ω ). Individual utility, given optimal medical spending, is then given by
(3)  u ∗ (λ, ω) = u( m ∗ (λ, ω); λ, ω) = y − c · λ +  1 __
2
 (1 − c) 2 ω. 
5 For concreteness, we model heterogeneity in the behavioral response to price, since this is what we document 
in the empirical results. In principle, one could derive similar analyses with behavioral heterogeneity in the response 
to other aspects of the contract, such as coverage of “star” hospitals, as in Shepard (2015). 
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To facilitate intuition of the model, consider the case of full coverage ( c = 0 ) 
and no insurance ( c = 1 ). In these cases, equation (2) indicates that the individual 
would spend  m c=1 ∗ = λ with no insurance and  m c=0 ∗ = λ + ω with full insurance. 
Thus, individual medical spending depends on both a “level” term  λ and a “slope” 
term  ω . The individual has a level spending  λ no matter what coverage he faces, but 
he then spends an additional  ω when he has full coverage and does not need to pay 
for this additional utilization out of pocket. It is natural to view  λ as related to the 
individual health, reflecting health conditions that need to get treated regardless of 
insurance coverage.
This  ω term is typically referred to as “moral hazard” in the health economics 
literature (Pauly 1968). The structural interpretation of  ω is not obvious. It likely 
reflects a combination of individual preferences over health and income as well 
as the nature of his health conditions and the extent to which treatment or type of 
treatment is optional or discretionary. Fortunately, the exact interpretation of  ω is 
not crucial for the main point we try to advance in this paper, although our empir-
ical work shed some light on the individual characteristics that correlate with  ω . 
Rather, the key point is that two different economic objects—health  λ and behav-
ioral response to insurance contract  ω —determine medical spending  m .
B. relation to Empirical Work
The empirical results shown in Figure 3 provide a simple illustration of one of 
the two key points of the paper: a one-dimensional summary measure is unlikely to 
be sufficient in describing individual types. The combination of generally monotone 
patterns in average individual characteristics as a function of annual drug spend-
ing and systematic nonmonotonicity around the kink suggests that individuals vary 
not only in the health ( λ ) but also in their responsiveness to contract features like 
price ( ω ). Our results also indicate which types of individuals exhibit greater price 
sensitivity: those who “bunch” at the kink are younger, more likely to be male, and 
appear healthier on many—but not all—measures of health conditions. These indi-
viduals appear to have greater flexibility regarding prescription filling. The results 
therefore suggest that in our setting, at least for individuals around the kink, under-
lying health  λ and price sensitivity  ω are negatively correlated. The fact that the 
greater price responsiveness is more pronounced for some health measures but not 
for others underscores the richness of the potential underlying heterogeneity; our 
summary health measure  λ itself likely encodes a richer heterogeneity, although in 
the context of our simple model a two-dimensional description of individuals would 
be sufficient.
This visual evidence of multidimensional heterogeneity complements our pre-
vious work where we estimated multidimensional heterogeneity in the context 
of a specific structural model of insurance demand, and explored its implications 
for consumer selection of insurance coverage with different levels of cost sharing 
(Einav et al. 2013). Here, the empirical evidence of heterogeneity along two dimen-
sions—moral hazard type as well as health type—is relatively model-free (and 
arguably more compelling), coming directly from the data and the research design 
provided by the kink in the budget set. Our substantive focus here is also different. 
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We  examine whether this multidimensional heterogeneity is captured by current risk 
scoring models, and the resultant implications.
Figure 4 illustrated the other key empirical point in the paper: current risk-score 
methods do not capture the behavioral responsiveness ( ω ) dimension of individual 
heterogeneity. This is by design, not only in the Medicare context but in most other 
risk-adjustment models around the world (Ellis 2008). The Medicare risk scores 
attempt to predict  m under a particular contract; they are constructed by employing 
a statistical predictive approach that attempts to find the best predictor of observed 
cost under Medicare Fee for Service. They therefore do not attempt to model how 
costs might vary across individuals under some other insurance contract in which 
individual behavior might differ from what is observed under Medicare Fee for 
Service, and which there might be heterogeneity across individuals in this behav-
ioral response. Without an economic model of how costs under one contract may 
differ from those under another due to individual choices (and the potential hetero-
geneity in this difference across individuals), or a separate observed outcome that 
would allow the risk adjustment to observe or proxy for this second dimension of 
heterogeneity, it would be difficult to capture a second dimension of heterogeneity.
C. cream-skimming Incentives
We briefly explore some of the theoretical implications of the fact that current 
risk scores do not attempt to capture cost heterogeneity arising from heterogeneity 
in behavioral responses to a contract. The Appendix provides a highly stylized theo-
retical example that illustrates how cream-skimming incentives can still exist in the 
presence of a “perfect” risk score under a given contract when individuals are het-
erogeneous in their behavioral responses to contracts. In the context of our model, a 
statistically “perfect” risk score means that there are no residual characteristics that 
predict an individual’s  λ i +  ω i conditional on their risk score. We briefly summarize 
the example and findings here.
We assume that the government offers a default contract, and consider a private 
(monopolist) insurer who offers a contract that competes to attract beneficiaries 
from the default contract.6 We assume the default public coverage provides full 
insurance (i.e.,  c = 0 ), while the private plan has a technology to completely elim-
inate  ω -related medical spending. Thus, in our stylized framework—see especially 
equations (2) and (3)—beneficiary  i  chooses medical spending level  λ i +  ω i under 
the public option, but only spends  λ i if enrolled by the private plan. The government 
reimburses the private insurer based on the risk scores of the beneficiaries it attracts. 
Because the government can only observe medical spending under its own, public 
contract, it can only set risk scores for beneficiaries and reimburse the private pro-
vider based on enrollees’ medical spending under the public contract ( λ i +  ω i ). As 
6 One loose, real-world analog might be the Medicare Advantage plans offered by private insurers who compete 
to attract beneficiaries from traditional fee-for-service-Medicare (Newhouse et al. 2012). Of course, for simplicity 
we have considered a monopolist competing against a (passive) public option, whereas oligopoly is presumably a 
more sensible assumption for the real-world Medicare Advantage plans. 
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Figures 3 and 4 illustrate empirically, this risk score does not distinguish between 
beneficiary costs arising from  λ or from  ω .
Under these assumptions, the socially efficient allocation is for everyone to be 
covered by the private plan, which eliminates inefficient,  ω -related medical utiliza-
tion. However, enrollees obtain greater utility in the less restrictive, public coverage, 
forcing the government to provide subsidies (potentially as a function of the risk 
score) to the private plan in order for it to have incentives to attract enrollees through 
lower premiums. This creates a tradeoff for government policy: greater subsidies 
create a more efficient allocation, but at the cost of higher public expenditures, and 
thus a greater social cost of public funds.
We analyze equilibrium selection into the private plan for a given government 
subsidy policy; a subsidy policy defines the government subsidy amount provided to 
the private plan for enrolling an individual with a given risk score. For a given sub-
sidy policy, there are two conflicting selection pressures. On the one hand, higher- ω 
individuals are the most profitable for the private insurer to enroll and therefore the 
private insurer has an incentive to try to attract these individuals. On the other hand, 
higher- ω individuals are also the ones with the greatest incentive to remain under 
the public coverage.
The Appendix presents a standard mechanism design solution to this conflict 
of incentives. It shows that, in equilibrium, the highest- ω individuals enroll in the 
private plan. These are the individuals for whom the efficiency benefits of the pri-
vate plan are highest. However, the socially efficient outcome of having everyone 
enrolled in the private plan may not be the constrained optimum given the social cost 
of the public funds required to achieve it.
We can in fact solve for the optimal subsidy by the government as a function 
of the equilibrium solution to a given subsidy level. The optimal subsidy problem 
resembles a standard optimal pricing problem. Our discussion in the Appendix high-
lights some of the key economic objects that determine the optimal subsidy, and 
which would need to be estimated in any particular application designed to analyze 
optimal risk adjustment in this environment.
IV. Conclusions
Our objective in this paper was to highlight the fact that risk scores that are com-
monly used in credit and insurance markets are not merely statistical objects, as 
they are generated by economic behavior. We illustrated this point empirically in the 
specific context of Medicare Part D, the public prescription drug insurance program 
that covers over 30 million individuals, and explored their implications theoreti-
cally. We exploited the famous “donut hole” where insurance becomes discontinu-
ously much less generous at the margin.
Using this research design, we empirically illustrated two conceptual points. 
First, analyzing the average demographic and health characteristics of individuals 
as a function of annual drug spending, we showed that spending differences across 
individuals reflect not only heterogeneity in underlying health but also heterogene-
ity in the underlying behavioral response to the insurance contract. Second, we show 
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that the current (statistical) risk scores—which are designed to predict spending 
under a given contract—do not capture this second dimension of heterogeneity.
In the second part of the paper, we used a highly stylized theoretical example 
to explore some of the potential implications of these findings for the standard use 
of risk scores, which is to predict outcomes out of sample under other contracts 
and use these predictions to set reimbursement rates. We showed that standard risk 
scoring can create incentives for private insurers to cream-skim individuals whose 
(unpriced) behavioral response to the contract they offer will make them have a 
lower cost than what is predicted by the risk score that was generated under a dif-
ferent contract. A key point is that, when there is heterogeneity in the behavioral 
response to the contract, these cream-skimming incentives can still exist even in 
the presence of “perfect” risk scoring under a given contract. While we thus illus-
trated, in the context of a specific theoretical example, the possibility of equilibrium 
selection on the behavioral response to different contracts, we did not establish its 
empirical existence or importance in a specific context. This would be a natural area 
for future work.
One potential response to the multidimensional heterogeneity we document is 
to move beyond a one-dimensional risk score and customize the risk-score formula 
to the specific contracts to which it is applied. Risk scoring is currently conducted 
as a statistical prediction exercise of behavior under a given contract without any 
such adjustment, while our paper suggests the need to consider economic as well as 
statistical forces in designing risk scoring that is applied to other contracts. In prac-
tice, to do so would require empirical estimates of the heterogeneity in the behav-
ioral response to alternative counterfactual contracts—perhaps of the flavor of those 
shown in Section II. Given the increased reliance on various models of risk scoring 
in many important markets, we view such analysis of optimal risk scoring in the 
presence of multidimensional heterogeneity in specific credit and insurance con-
texts to be an interesting—and potentially important—area for future work.
Appendix: An Illustrative Example of Cream-Skimming Incentives
In this Appendix we use a simple example to illustrate how cream-skimming 
incentives can still exist in the presence of a “perfect” risk score under a given 
contract when individuals are heterogeneous in their behavioral responses to con-
tracts. We also consider the optimal risk-adjustment policy for the government in the 
 presence of such incentives.
For concreteness, we consider a specific, highly-stylized environment. Our objec-
tive is not to derive results that can be directly applied to a specific real-world con-
text, but simply to help illustrate the potential new considerations that come into 
play as a result of the richer heterogeneity documented in the paper.
setting.—We assume the government offers a default contract, and consider a pri-
vate (monopolist) insurer who offers a contract that competes to attract beneficiaries 
from the default contract. The government reimburses the private insurer based on 
the risk scores of the beneficiaries it attracts. The key point is that an individual’s 
medical spending may differ under the private contract and the government default 
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contract. We show how this impacts provider cream-skimming incentives under a 
given set of reimbursement rules.
For simplicity, we assume that the default public coverage provides full insurance 
(i.e.,  c = 0 in the framework of Section III). As a result, in our framework—see 
especially equations (2) and (3)—beneficiary  i  , who can be fully described by his 
two-dimensional type ( λ i ,  ω i ), chooses medical spending level  λ i +  ω i and obtains 
utility  u i ∗ =  y i +  ω i /2 . The associated government spending  g i is then  λ i +  ω i . 
These assumptions are summarized in the first three rows of Appendix Table A2 in 
the first column to make them more easily comparable to our assumptions about the 
private plan, summarized in the second column.
We make the (extreme) assumption that the private plan can completely eliminate 
ω -related medical spending. In other words, they can incentivize physicians to “per-
fectly” distinguish medical spending associated with  λ i —that is, medical spending 
that would have been made by the beneficiary even with no coverage—from med-
ical spending associated with  ω i , which would not have occurred if the beneficiary 
was uninsured. Moreover, we assume that the private plan will only cover  λ i -related 
medical spending. Under the private plan therefore, medical spending associated 
with beneficiary  i is  λ i and he obtains utility  u i ∗ =  y i as summarized in Appendix 
Table A2.
The government reimburses the private insurer based on the current Medicare 
risk scores of the beneficiaries it enrolls; we denote these risk scores by  r i . We 
assume that the government can only observe medical spending under its own, pub-
lic contract, and thus can only score beneficiaries based on their predicted medical 
spending under the public contract. Risk scoring is thus based on a prediction model 
of medical spending under public coverage. Specifically, the risk score  r i is medical 
spending under the public plan;  r i =  λ i +  ω i . As Figures 3 and 4 illustrated empir-
ically, this risk score does not distinguish between beneficiary costs arising from  λ 
or from  ω . In keeping with our focus on a challenge to risk scoring that exists even 
if risk scores are “perfect” in the statistical sense, we also assume here that there are 
no residual characteristics of the individual that predict  λ i +  ω i conditional on  r i .
Given this “perfect” risk score  r i , private insurers receive a risk-adjusted transfer 
from the government,  g( r i ) , for covering beneficiary  i . It will be convenient to define 
g( r i ) ≡  r i + s( r i ) as the sum of the cost this beneficiary would have incurred under 
the public plan,  r i , and an additional (positive or negative) subsidy  s( r i ) . Therefore, 
as shown in row 3 of Appendix Table A2, government spending  g i under the public 
plan is given by beneficiary medical spending under this plan  λ i +  ω i , and under the 
private plan it is given by  g( r i ) =  λ i +  ω i + s( λ i +  ω i ) .
As shown in row 4, insurer profits  π i from covering individual  i are given by the 
government (risk-adjusted) transfer  g( r i ) minus the cost to the insurer of covering 
individual  i under the offered contract; private provider costs are  λ i by assumption.7
The bottom row of Appendix Table A2 shows the implications of each insurance 
allocation for total surplus associated with beneficiary  i . We define total surplus as 
7 We abstract from any administrative costs of the private insurer which will not affect the fundamental selection 
analysis. 
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the sum of consumer surplus and producer surplus, minus government spending 
(and its associated costs). For individual  i it is given by
(A1)  T  s i =  u i ∗ +  π i − (1 + k )  g i ,  
where  k is the shadow cost of public funds.
Given our assumptions, it is socially efficient for everyone to be covered by the 
private plan if there is no subsidy ( s(  r i ) = 0 ), with the gain in efficiency from 
enrolling beneficiary  i in the private plan increasing in  ω i . This is because we have 
assumed that under the private plan, insurance coverage is still full, but does not 
apply to  ω i -related medical spending; and under the assumptions of our model, 
 ω i -related medical spending is socially inefficient. As a result, total surplus under 
the private plan is higher by  0.5  ω i for any beneficiary  i (see row 5 of Appendix 
Table A2). However, as we will see below, the private provider would not find it 
optimal to cover all beneficiaries due to cream-skimming incentives, so an addi-
tional government subsidy  s( r i ) would be needed to get more beneficiaries enrolled 
in the private plan. Optimal risk adjustment would thus trade off these two offsetting 
forces: increasing allocative efficiency from inducing more individuals to be cov-
ered by the private plan against the social cost of public funds for the subsidy needed 
to enroll additional individuals in the private plan.
Private Provider optimization Problem.—We now consider the impact of the 
foregoing setup for the provider’s optimal (profit-maximizing) contracts and, there-
fore, for equilibrium cream-skimming. We model the monopolist private insurer’s 
problem as a standard optimal contracting model with incomplete information.
The private provider observes the risk score  r (which, recall, is simply spending 
under the public contract) and offers a family of contracts that are a function of the 
observed risk score  r and a self-reported (by beneficiaries) type  ω ′. If a beneficiary 
chooses a contract  p(r, ω′ ) , he would pay a premium  p(r, ω′ ) to the private insurer, 
and the private insurer would cover medical spending of  λ′ = r − ω ′ ; we note that, 
under our assumptions, this is the efficient amount of medical spending for someone 
with risk score  r and type  ω ′. We assume that people know their true type ( λ, ω ) 
when choosing insurance plans. Insurers then design the contracts such that each 
beneficiary truthfully reveals his type, thus allowing the private provider to only 
authorize the  λ -related medical spending associated with the true  λ .
Consider the utility of beneficiary of type  (λ, ω) from a private contract  p(r, ω′ ) . 
Recall that  r = λ + ω is observed, and that individual medical spending under the 
private contract would be given by  λ′ = r − ω′ = λ + ω − ω ′. Plugging this into 
the utility function in equation (1) we obtain utility under the private contract:
(A2)  u(λ, ω; ω′ ) =  [ (ω − ω′ ) −  1 ___ 2ω  (ω − ω′ ) 2 ] + y − p(r, ω′ ). 
By contrast, staying in the public plan would result in utility of  y + 0.5 ω , as derived 
earlier (see Appendix Table A2).
Because  r is observed and contractible, we can then solve the profit maximiza-
tion problem of the private provider separately for each  r . We denote by  F ω|r the 
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 conditional (on  r ) cumulative distribution function of  ω . The private provider’s 
problem is to choose the menu of contracts  p(r, ω′ ) in order to maximize profits:
(A3)  max 
p(r, ω)
  π(r)  =  ∫     [ p(r, x)  + g(r)  − (r − x)]  d  F ω|r (x) 
 =  ∫     [ p(r, x)  + s(r)  + x] d  F ω|r (x),  
subject to an incentive compatibility (IC) constraint that makes beneficiaries choose 
the contract that matches their type
(A4)  u(λ, ω; ω) = y − p(r, ω) ≥ u(λ, ω; ω′ )  ∀ ω ′,  
and an individual rationality (IR) constraint that makes beneficiaries willing to opt 
out of the public plan and instead enroll in private coverage
(A5)  u(λ, ω; ω) = y − p(r, ω) ≥ y + ω / 2. 
The IC constraint can be written as  ω = arg  max ω ′  u(λ, ω; ω′ ) . A necessary and 
sufficient condition is that the IC constraint’s first-order condition holds. Solving 
the IC constraint using utility from the private contract defined in equation (A2), 
gives  − 1 − ∂ p / ∂ ω = 0 , implying that  p(r, ω) = t(r)  − ω , where  t(r) is the inte-
gration constant (which could depend on  r , as the solution is conditional on  r ). 
Substituting this schedule into the IR constraint above (equation (A5)), we obtain 
y − (t(r)  − ω) ≥ y + ω / 2 . Thus, selection into private coverage is given by:
(A6)  ω ≥ 2t(r). 
Equation (A6) describes equilibrium selection under the profit maximizing con-
tract: for every risk score  r , higher  ω beneficiaries select into the private contract 
while lower  ω beneficiaries remain in the public plan. Thus, on one hand, selection 
will be in general favorable: the beneficiaries for whom it is most socially efficient 
to be covered by the private provider will be covered by the private provider. On 
the other hand, because risk scoring does not capture this second dimension of het-
erogeneity, some fraction of beneficiaries will inefficiently remain covered by the 
public plan.
Given the equilibrium selection rule in equation (A6), the profit maximization 
problem from equation (A3) becomes
(A7)  max 
t(r) 
  π(r) = (t(r) + s(r))  Pr   
 (ω ≥ 2t(r)  | r) =  (t(r) + s(r))  [1 −  F ω|r (2t(r))] . 
The monopolist therefore sets  t ∗ (r) to solve the first-order condition
(A8)  t ∗ (r) =  1 −  F ω|r (2  t 
∗ (r))  ____________
2   f ω|r (2  t ∗ (r)) − s(r) ,  
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with  f ω|r (x) =  F ω | r ′ (x) .
This is a familiar profit maximization problem, very similar to the textbook opti-
mal pricing problem for a monopolist facing a downward sloping unit demand curve. 
The profit function in equation (A7) has the familiar form of  π = ( p − c) D( p) 
where, here, price  p is given by  t(r) , marginal cost  c is given by  − s(r) , and demand 
D( p) is given by  1 − F . As in the textbook case, the monopolist trades off price 
versus quantity: raising the price  t(r) will result in greater profits on inframarginal 
beneficiaries, but a loss of marginal beneficiaries to the public plan. The extent of the 
loss of marginal beneficiaries (and hence the optimal price  t(r) ) depends on the shape 
of the demand curve, which in this case depends on the hazard rate of the distribu-
tion of  ω . The problem becomes similar to the textbook monopolist pricing problem 
because the private provider does not observe  ω , and his cream-skimming incen-
tive—the greater profit he obtains from higher- ω beneficiaries—is exactly offset by 
the increased incentive of the higher- ω beneficiaries to remain in the public plan.
Implications for Designing risk Adjustment.—The analogy to the monopolist 
pricing problem also makes it easy to see the role that alternative risk-adjustment 
formulations could play. Looking at equation (A7), the government subsidy  s(r) 
can be thought of as shifting the monopolist’s marginal cost, since  s(r) enters the 
profit function just like the negative of marginal cost. This yields clear and natural 
comparative statics: an increase (decrease) in the subsidy  s(r) would provide more 
(less) powerful incentives to the private provider to enroll additional beneficiaries 
by reducing (increasing) the “unit price”  t(r) . Therefore, as can be seen directly in 
equation (A8), changes in the subsidy  s(r) are partially passed through to the pre-
mium  p ∗ (r, ω) =  t ∗ (r) − ω . The government subsidy affects the private provider’s 
profit maximizing pricing, and thereby affects the equilibrium selection of individ-
uals to the private plan.
Absent any social cost of public funds, the bottom row of Appendix Table A2 
makes it clear that the optimal subsidy should be high enough, so that the private 
provider would set  t(r) = 0 and thereby, by equation (A6), enroll all beneficia-
ries. However, when the social cost of public funds is positive ( k > 0 ), the optimal 
subsidy is set to resolve a simple tradeoff: higher  s(r) would efficiently enroll more 
beneficiaries under the private plan, but would be associated with greater costs of 
public funds.
To see this tradeoff more formally, consider the government’s optimization 
problem. For a given risk score  r , the government chooses the optimal transfer 
g ∗ (r) = r +  s ∗ (r) in order to maximize total surplus subject to the private insurer 
setting  t ∗ (s(r); r) optimally.
Relative to the total surplus that would arise from covering all beneficiaries in the 
public plan, the incremental surplus from allocating an individual to the private plan 
instead is then given by
(A9)  ΔTs(s(r); r) 
  =  [ 1 __2 E [ω | ω ≥   F ω|r (2  t ∗ (s(r); r))] − ks(r)] [1 −  F ω|r (2  t ∗ (s(r); r))] . 
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By increasing  s(r) the government indirectly decreases  t ∗ (r) and thus (socially effi-
ciently) enrolls more beneficiaries in the private plan, at the cost of increasing the 
cost of public funds for all inframarginal beneficiaries who were already enrolled in 
the private plan. For a given risk score  r , the government would optimally set  s(r) 
to maximize  ΔTs(s(r); r) , with the optimal subsidy  s(r) decreasing in the cost of 
public funds  k. 
Thus far, we have considered the optimal government subsidy  s ∗ (r) for a given 
r . Our analysis has shown that the optimal risk adjustment—the function  g(r) , or 
equivalently the subsidy  s(r) = g(r) − r —can be solved for each  r separately. 
Analysis of optimal risk adjustment requires determining how the optimal subsidy 
s ∗ (r) varies with  r . This is in the spirit of inquiry of Glazer and McGuire (2000), 
who found (in their unidimensional heterogeneity model) that the optimal risk 
adjustment should amplify the observed risk scores.
A full characterization of  s(r) would require assumptions (or ideally evidence) 
about the specific objects, most importantly about the distribution  F ω|r , which deter-
mines the shape of the demand curve, and the social costs of public funds  k , which 
determines the cost of subsidies designed to increase the set of people (efficiently) 
covered by the private provider.8 The social cost of public funds is typically assumed 
to be about 0.3 (Poterba 1996). The conditional distribution  F ω|r —i.e., the shape of 
unobserved (by the government) individual type conditional on observed individual 
spending under the government contract—would need to be estimated in the  specific 
application. In our empirical context, for example, some evidence on the shape of 
this function was provided by our analysis of who “bunches” at the kink in the 
donut hole. Figure 3 indicated that healthier individuals were more likely to bunch 
at the kink, suggesting that  ω and  λ are negatively correlated, at least around the 
donut hole, which may provide some guidance regarding  F ω|r (recall, in our example 
r = ω + λ ).
8 Under a given set of assumptions about  k and  F ω|r ( · ) , it is easy (although typically cumbersome) to solve 
for the optimal  s(r ) . For example, inspection of equation (A9) indicates that if  ω | r is uniformly distributed over 
[0, A(r)] , the optimal subsidy  s ∗ (r) would scale proportionally with  A(r) . For the general case, however, the optimal 
s(r)  could be either positive or negative, and could either increase or decrease (or not even be monotone) in  r . 
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Appendix Table A1—Risk-Type Ranking under Alternative Contract Designs
Spending under  
standard contract Predicted spending under counterfactual contract
Percentile 
range
(1)
Average 
spending
(2)
Move >1  
bin down
(3)
Move 1  
bin down
(4)
Remain in same 
bin
(5)
Move 1  
bin up
(6)
Move >1 
bin up
(7)
Panel A. counterfactual contract “fills” the coverage gap
0–12a 0 — — 0.99 0.00 0.00
12–15a 15 — 0.00 0.99 0.00 0.00
15–20 65 0.00 0.01 0.98 0.00 0.00
20–25 227 0.00 0.01 0.98 0.01 0.00
25–30 527 0.00 0.02 0.96 0.01 0.01
30–35 760 0.00 0.03 0.92 0.02 0.02
35–40 950 0.00 0.07 0.87 0.04 0.03
40–45 1,128 0.00 0.10 0.83 0.04 0.04
45–50 1,305 0.00 0.13 0.78 0.04 0.04
50–55 1,489 0.00 0.17 0.71 0.06 0.06
55–60 1,691 0.00 0.22 0.65 0.06 0.07
60–65 1,916 0.00 0.27 0.57 0.07 0.09
65–70 2,162 0.00 0.34 0.45 0.10 0.12
70–75 2,404 0.00 0.43 0.32 0.13 0.12
75–80 2,590 0.00 0.43 0.32 0.17 0.09
80–85 2,843 0.11 0.39 0.29 0.14 0.07
85–90 3,296 0.07 0.40 0.36 0.13 0.04
90–95 4,140 0.01 0.37 0.52 0.10 —
95–100 7,394 0.00 0.21 0.79 — —
Panel B. counterfactual contract removes deductible and increases pre-gap cost sharing
0–12a 0 — — 0.68 0.08 0.24
12–15a 15 — 0.50 0.12 0.16 0.21
15–20 65 0.38 0.15 0.22 0.14 0.11
20–25 227 0.27 0.36 0.22 0.09 0.06
25–30 527 0.05 0.38 0.41 0.11 0.05
30–35 760 0.03 0.24 0.58 0.12 0.04
35–40 950 0.03 0.14 0.62 0.18 0.02
40–45 1,128 0.04 0.11 0.61 0.21 0.02
45–50 1,305 0.05 0.11 0.58 0.25 0.02
50–55 1,489 0.06 0.10 0.57 0.26 0.01
55–60 1,691 0.06 0.09 0.58 0.26 0.01
60–65 1,916 0.07 0.08 0.62 0.23 0.00
65–70 2,162 0.06 0.09 0.64 0.21 0.00
70–75 2,404 0.05 0.09 0.66 0.20 0.01
75–80 2,590 0.04 0.10 0.71 0.16 0.00
80–85 2,843 0.05 0.07 0.78 0.09 0.01
85–90 3,296 0.03 0.05 0.86 0.06 0.00
90–95 4,140 0.01 0.05 0.92 0.02 —
95–100 7,394 0.01 0.01 0.98 — —
notes: The table is based on the baseline estimates from a behavioral model of healthcare spending developed and 
estimated in Einav, Finkelstein, and Schrimpf (2015). In the figure, we use those estimates to simulate healthcare 
spending under the standard Part D coverage contract shown in Figure 1, and under two counterfactual contracts: 
a “filled gap” contract (panel A) and a “no deductible” contract (panel B). The filled gap contract eliminates the 
gap by providing pre-gap coverage through the catastrophic limit, while the no-deductible contract eliminates the 
deductible but offers higher cost sharing (up to the gap) of 38.9 (rather than 25) cents on the dollar, thus leading to 
the same expected cost to the insurer. To construct the  figure, we use the model and baseline estimates from Einav, 
Finkelstein, and Schrimpf (2015), and simulate 43,000 individuals and associated sequences of health shocks (that 
are held fixed across contracts). The table entries show the proportion of individuals whose spending ventile gets 
reshuffled as they move from the standard contract to the alternative contract. Absent heterogeneity in the response 
to price, all individuals would have stayed in the same spending ventile, and all entries in column 5 would be equal 
to 1, and all other entries—columns 3, 4, 6, and 7—would be zero. Heterogeneity in the response to price leads 
to some individuals moving up and others moving down in the spending distribution in response to the change in 
coverage.
a The  first two spending bins are different in size because of the mass point (of 12 percent) of individuals with 
zero spending under the standard contract.
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